PDCD1 and non-small cell lung carcinoma: A trial (NCT03425006) that utilised sequential JAKi and anti-PD-L1 antibodies revealed enhanced clinical responses in patients with metastatic non-small cell lung cancer, particularly when administered after discontinuing treatment with anti-PD-1 antibodies [99].